US 11,452,781 B2 · Method of preventing and treating type 1 diabetes, allograft rejection and lung fibrosis (by targeting the ATP/P2X7R axis)

Abstract

The present invention relates to the role of purinergic receptors and ATP in T cell activation and autocrine system signaling. In one embodiment, the present invention provides a method of preventing or treating diabetes by administering a therapeutically effective inhibitor of ATP to a subject. In another embodiment, the present invention provides a method of preventing or treating fibrosis by administering a P2X7R soluble fusion protein. In another embodiment, the present invention provides a method of preventing or treating graft rejection by administering an inhibitor of P2X receptor signaling.

Claims3

Dependent claims

A method of delaying the onset of type 1 diabetes in a subject in need thereof, comprising administering a therapeutically effective dosage of a polypeptide comprising the ectodomain of purinoceptor type 2 subtype 1 family member 7 receptor (P2X7R) to the subject.

Dependencies are inferred from the claim text.

Facts

Application

16/054,412Filed 3 Aug 2018 · continuation

Priority

8 May 2013

Published

US 2019/0184027 A120 Jun 2019

Granted

27 Sep 2022

Term ends

Not estimatedThe source records don’t support an estimate.

Classification8 codes

A61K 31/436
Ortho- or peri-condensed with heterocyclic ring systems: the heterocyclic ring system containing a six-membered ring having oxygen as a ring…
A61K 31/166
Having aromatic rings, e.g. colchicine, atenolol, progabide: having the carbon of a carboxamide group directly attached to the aromatic ring, e.g.…
A61K 31/402
Having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil: 1-aryl substituted,…
A61K 31/53
Having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins: having six-membered rings with three nitrogens as the only ring hetero…

Family

Application61/820,763Us provisional application · filed 8 May 2013

PCT/US2014/036755Parent of this continuation · filed 5 May 2014

US 2019/0184027 A1Pre-grant publication · published 20 Jun 2019

Application14/786,424Parent of this continuation

US 10,071,167 B2Parent of this continuation

US 2016/0067348 A1Published application

US 11,452,781 B2This patent

From the US filing history. Foreign family members aren’t listed.

Abstract

Facts

Application

16/054,412Filed 3 Aug 2018 · continuation

Priority

8 May 2013

Published

US 2019/0184027 A120 Jun 2019

Granted

27 Sep 2022

Term ends

Not estimatedThe source records don’t support an estimate.

Classification8 codes

A61K 31/436
Ortho- or peri-condensed with heterocyclic ring systems: the heterocyclic ring system containing a six-membered ring having oxygen as a ring…
A61K 31/166
Having aromatic rings, e.g. colchicine, atenolol, progabide: having the carbon of a carboxamide group directly attached to the aromatic ring, e.g.…
A61K 31/402
Having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil: 1-aryl substituted,…
A61K 31/53
Having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins: having six-membered rings with three nitrogens as the only ring hetero…

Family

Application61/820,763Us provisional application · filed 8 May 2013

PCT/US2014/036755Parent of this continuation · filed 5 May 2014

US 2019/0184027 A1Pre-grant publication · published 20 Jun 2019

Application14/786,424Parent of this continuation

US 10,071,167 B2Parent of this continuation

US 2016/0067348 A1Published application

US 11,452,781 B2This patent

From the US filing history. Foreign family members aren’t listed.

Method of preventing and treating type 1 diabetes, allograft rejection and lung fibrosis (by targeting the ATP/P2X7R axis)

Life of this patent

Abstract

Claims3

Method of preventing and treating type 1 diabetes, allograft rejection and lung fibrosis (by targeting the ATP/P2X7R axis)

Life of this patent

Abstract

Claims3